Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 3, 2011, Pages 726-736

  White, Helen D ^a   Ahmad, A M ^a   Durham, B H ^b   Joshi, A A ^a   Fraser, W D ^b   Vora, J P ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CYCLIC AMP; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; PARATHYROID HORMONE; PHOSPHATE; SOMATOMEDIN C;

ADJUVANT THERAPY; ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE TURNOVER; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG INDUCED HEADACHE; FEMALE; FEMUR NECK; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; JOINT SWELLING; LUMBAR SPINE; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADMINISTRATION, ORAL; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CIRCADIAN RHYTHM; COLLAGEN TYPE I; CYCLIC AMP; DRUG THERAPY, COMBINATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PEPTIDES; PHOSPHATES; RECOMBINANT PROTEINS;

EID: 79952288621     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1929     Document Type: Article

References (42)

1. Boonen S, Lesaffre E, Aerssens J, Pelemans W, Dequeker J, Bouillon R 1996 Deficiency of the growth hormone-insulin-like growth factor-I axis potentially involved in age-related alterations in body composition. Gerontology 42:330-338 (Pubitemid 26375685)
2. Wüster C, Slenczka E, Ziegler R 1991 [Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?]. Klin Wochenschr 69:769-773
3. Rosén T, Hansson T, Granhed H, Szucs J, Bengtsson BA 1993 Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 129:201-206 (Pubitemid 23295680)
4. Johansen JS, Pedersen SA, Jørgensen JO, Riis BJ, Christiansen C, Christiansen JS, Skakkebaek NE 1990 Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults. J Clin Endocrinol Metab 70:916-919
5. Kelly PA, Ali S, Rozakis M, Goujon L, Nagano M, Pellegrini I, Gould D, Djiane J, Edery M, Finidori J 1993 The growth hormone/prolactin receptor family. Recent Prog Horm Res 48:123-164
6. Fraser DR, Kodicek E 1973 Regulation of 25-hydroxycholecalciferol-1- hydroxylase activity in kidney by parathyroid hormone. Nat New Biol 241:163-166
7. Fujimori A, Cheng SL, Avioli LV, Civitelli R 1992 Structure-function relationship of parathyroid hormone: activation of phospholipase-C, protein kinase-A and -C in osteosarcoma cells. Endocrinology 130:29-36
8. el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA 1997 The parathyroid hormone circadian rhythm is truly endogenous - a general clinical research center study. J Clin Endocrinol Metab 82:281-286
9. Fraser WD, Logue FC, Christie JP, Gallacher SJ, Cameron D, O'Reilly DS, Beastall GH, Boyle IT 1998 Alteration of the circadian rhythm of intact parathyroid hormone and serum phosphate in women with established postmenopausal osteoporosis. Osteoporos Int 8:121-126 (Pubitemid 28230433)
10. Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP 2008 Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res 23:721-729 (Pubitemid 351575026)
11. Ahmad AM, Hopkins MT, Fraser WD, Ooi CG, Durham BH, Vora JP 2003 Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. Bone 32:170-179 (Pubitemid 36299145)
12. Ahmad AM, Thomas J, Clewes A, Hopkins MT, Guzder R, Ibrahim H, Durham BH, Vora JP, Fraser WD 2003 Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism. J Clin Endocrinol Metab 88:2860-2868 (Pubitemid 36724468)
13. Ahmad AM, Hopkins MT, Thomas J, Durham BH, Fraser WD, Vora JP 2004 Parathyroid responsiveness to hypocalcaemic and hypercalcaemic stimuli in adult growth hormone deficiency after growth hormone replacement. Am J Physiol Endocrinol Metab 286: E986-E993 (Pubitemid 38668823)
14. White HD, Ahmad AM, Syed AA, Clewes A, Peter R, Vora JP, Fraser WD 2004 Gender variation in PTH sensitivity and rhythmicity following growth hormone replacement in adult growth hormone-deficient patients. Clin Endocrinol (Oxf) 60:516-526 (Pubitemid 38482516)
15. White HD, Ahmad AM, Durham BH, Patwala A, Whittingham P, Fraser WD, Vora JP 2005 Growth hormone replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult growth hormonedeficient patients. J Clin Endocrinol Metab 90:3371-3380 (Pubitemid 41014300)
16. Silverberg SJ, Shane E, Clemens TL, Dempster DW, Segre GV, Lindsay R, Bilezikian JP 1986 The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects. J Bone Miner Res 1:383-388
17. Naveh-Many T, Rahamimov R, Livni N, Silver J 1995 Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96:1786-1793
18. Jubiz W, Canterbury JM, Reiss E, Tyler FH 1972 Circadian rhythm in serum parathyroid hormone concentration in human subjects: correlation with serum calcium, phosphate, albumin, and growth hormone levels. J Clin Invest 51:2040-2046
19. Kilav R, Silver J, Naveh-Many T 1995 Parathyroid hormone gene expression in hypophosphatemic rats. J Clin Invest 96:327-333
20. Estepa JC, Aguilera-Tejero E, Lopez I, Almaden Y, Rodriguez M, Felsenfeld AJ 1999 Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res 14:1848-1854 (Pubitemid 29521779)
21. Ogle GD, Rosenberg AR, Kainer G 1992 Renal effects of growth hormone. II. Electrolyte homeostasis and body composition. Pediatr Nephrol 6:483-489
22. Lieberman SA, Holloway L, Marcus R, Hoffman AR 1994 Interactions of growth hormone and parathyroid hormone in renal phosphate, calcium, and calcitriol metabolism and bone remodeling in postmenopausal women. J Bone Miner Res 9:1723-1728 (Pubitemid 24341192)
23. Workshop GHRS 1998 Consensus guidelines for the diagnosis and treatment of adults with adult growth hormone deficiency. J Clin Endocrinol Metab 83:379-381
24. Ahmad AM, Hopkins MT, Thomas J, Ibrahim H, Fraser WD, Vora JP 2001 Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clin Endocrinol (Oxf) 54:709-717 (Pubitemid 34208881)
25. Gardner MD, Dryburgh FJ, Fyffe JA, Jenkins AS 1981 Predictive value of derived calcium figures based on the measurement of ionised calcium. Ann Clin Biochem 18:106-109 (Pubitemid 11093497)
26. White HD, Joshi AA, Ahmad AM, Durham BH, Vora JP, Fraser WD 2010 Correlation of serum-adjusted calcium with ionized calcium over a 24h period in patients with adult growth hormone deficiency before and after growth hormone replacement. Ann Clin Biochem 47:212-216
27. Walton RJ, Bijvoet OL 1975 Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309-310
28. Drezner MK, Neelon FA, Curtis HB, Lebovitz HE 1976 Renal cyclic adenosine monophosphate: an accurate index of parathyroid function. Metabolism 25:1103-1112
29. Mojón A, Fernández JR, Hermida RC 1992 Chronolab: an interactive software package for chronobiologic time series analysis written for the Macintosh computer. Chronobiol Int 9:403-412
30. Altman DG 1982 Statistics in medical journals. Stat Med 1:59-71
31. Reeve J, Arlot M, Bernat M, Charhon S, Edouard C, Slovik D, Vismans FJ, Meunier PJ 1981 Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: the influence of human parathyroid fragment (hPTH 1-34) therapy. Metab Bone Dis Relat Res 3:23-30
32. Netelenbos JC, van Ginkel FC, Lips P, Leeuwenkamp OR, Barto R, van der Vijgh WJ, van der Wiel H, Hackeng WH 1991 Effect of a single infusion of aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored during 2 months. J Clin Endocrinol Metab 72:223-228 (Pubitemid 21921680)
33. Valk NK, Erdtsieck RJ, Algra D, Lamberts SW, Pols HA 1995 Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass. Clin Endocrinol (Oxf) 43:317-324
34. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215 (Pubitemid 37152030)
35. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610
36. Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F 2001 Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J Clin Endocrinol Metab 86:3079-3085 (Pubitemid 32673468)
37. Samadfam R, Xia Q, Goltzman D 2007 Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology 148:2778-2787 (Pubitemid 46984814)
38. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs Jr RW, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
39. McCloskey EV, Yates AJ, Gray RE, Hamdy NA, Galloway J, Kanis JA 1988 Diphosphonates and phosphate homoeostasis in man. Clin Sci (Lond) 74:607-612
40. Iranmanesh A, Lizarralde G, Veldhuis JD 1991 Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the halflife of endogenous GH in healthy men. J Clin Endocrinol Metab 73:1081-1088 (Pubitemid 21901150)
41. Rudman D 1985 Growth hormone, body composition, and aging. J Am Geriatr Soc 33:800-807 (Pubitemid 16183980)
42. Finkelstein JW, Roffwarg HP, Boyar RM, Kream J, Hellman L 1972 Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab 35:665-670